These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 22406925)
1. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Crane CA; Ahn BJ; Han SJ; Parsa AT Neuro Oncol; 2012 May; 14(5):584-95. PubMed ID: 22406925 [TBL] [Abstract][Full Text] [Related]
2. Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study. Vasco C; Canazza A; Rizzo A; Mossa A; Corsini E; Silvani A; Fariselli L; Salmaggi A; Ciusani E J Neurooncol; 2013 Dec; 115(3):353-63. PubMed ID: 24005771 [TBL] [Abstract][Full Text] [Related]
3. Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma. Fu W; Wang W; Li H; Jiao Y; Huo R; Yan Z; Wang J; Wang S; Wang J; Chen D; Cao Y; Zhao J Front Immunol; 2020; 11():835. PubMed ID: 32457755 [TBL] [Abstract][Full Text] [Related]
4. More on the immune privilege of glioblastoma. Weller M Neuro Oncol; 2012 May; 14(5):527-8. PubMed ID: 22539528 [No Abstract] [Full Text] [Related]
5. CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. El Andaloussi A; Lesniak MS J Neurooncol; 2007 Jun; 83(2):145-52. PubMed ID: 17216339 [TBL] [Abstract][Full Text] [Related]
6. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115 [TBL] [Abstract][Full Text] [Related]
7. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Sayour EJ; McLendon P; McLendon R; De Leon G; Reynolds R; Kresak J; Sampson JH; Mitchell DA Cancer Immunol Immunother; 2015 Apr; 64(4):419-27. PubMed ID: 25555571 [TBL] [Abstract][Full Text] [Related]
8. Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells. Lin SZ; Chen KJ; Xu ZY; Chen H; Zhou L; Xie HY; Zheng SS Cancer Prev Res (Phila); 2013 Jun; 6(6):594-602. PubMed ID: 23599540 [TBL] [Abstract][Full Text] [Related]
9. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. Curtin JF; Candolfi M; Fakhouri TM; Liu C; Alden A; Edwards M; Lowenstein PR; Castro MG PLoS One; 2008 Apr; 3(4):e1983. PubMed ID: 18431473 [TBL] [Abstract][Full Text] [Related]
10. Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. Mrizak D; Martin N; Barjon C; Jimenez-Pailhes AS; Mustapha R; Niki T; Guigay J; Pancré V; de Launoit Y; Busson P; Moralès O; Delhem N J Natl Cancer Inst; 2015 Jan; 107(1):363. PubMed ID: 25505237 [TBL] [Abstract][Full Text] [Related]
11. Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence. Parodi A; Traverso P; Kalli F; Conteduca G; Tardito S; Curto M; Grillo F; Mastracci L; Bernardi C; Nasi G; Minaglia F; Simonato A; Carmignani G; Ferrera F; Fenoglio D; Filaci G Oncotarget; 2016 Feb; 7(6):6424-35. PubMed ID: 26824503 [TBL] [Abstract][Full Text] [Related]
12. MiR-568 inhibits the activation and function of CD4⁺ T cells and Treg cells by targeting NFAT5. Li W; Kong LB; Li JT; Guo ZY; Xue Q; Yang T; Meng YL; Jin BQ; Wen WH; Yang AG Int Immunol; 2014 May; 26(5):269-81. PubMed ID: 24355664 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance and mechanism of Treg infiltration in human brain tumors. Jacobs JF; Idema AJ; Bol KF; Grotenhuis JA; de Vries IJ; Wesseling P; Adema GJ J Neuroimmunol; 2010 Aug; 225(1-2):195-9. PubMed ID: 20537408 [TBL] [Abstract][Full Text] [Related]
14. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. El Andaloussi A; Lesniak MS Neuro Oncol; 2006 Jul; 8(3):234-43. PubMed ID: 16723631 [TBL] [Abstract][Full Text] [Related]
15. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity. Jayaraman P; Alfarano MG; Svider PF; Parikh F; Lu G; Kidwai S; Xiong H; Sikora AG Clin Cancer Res; 2014 Dec; 20(24):6439-51. PubMed ID: 25278453 [TBL] [Abstract][Full Text] [Related]
16. Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Pellegatta S; Poliani PL; Stucchi E; Corno D; Colombo CA; Orzan F; Ravanini M; Finocchiaro G Neuro Oncol; 2010 Apr; 12(4):377-88. PubMed ID: 20308315 [TBL] [Abstract][Full Text] [Related]
17. A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment. Cantini G; Pisati F; Mastropietro A; Frattini V; Iwakura Y; Finocchiaro G; Pellegatta S Cancer Immunol Immunother; 2011 Dec; 60(12):1739-50. PubMed ID: 21779877 [TBL] [Abstract][Full Text] [Related]
18. Human Endothelial Cells Modulate CD4 Lim WC; Olding M; Healy E; Millar TM Front Immunol; 2018; 9():565. PubMed ID: 29628925 [TBL] [Abstract][Full Text] [Related]
19. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246 [TBL] [Abstract][Full Text] [Related]
20. Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Wainwright DA; Sengupta S; Han Y; Lesniak MS Neuro Oncol; 2011 Dec; 13(12):1308-23. PubMed ID: 21908444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]